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Introduction
A most encountered problem in chemotherapy is tumor
resistance towards chemotherapy drugs. Hypoxic condition in
the microenvironment of the tumor is very likely caused by an
imbalance of oxygen supply and consumption due to limited
blood supply in rapidly proliferating tumor, resulting in
restricted oxygen diffusion and expansion of the hypoxic area. 1
The main factor that plays a role in the hypoxic state is
hypoxia–inducible factors (HIFs) protein. In hypoxic
conditions, HIF–1α becomes stable and undergoes
dimerization with β–subunit to form HIF–1, which in turn
activates the transcription process of proteins required to adapt
to hypoxia. Over expression of HIF–1α corresponds to
chemotherapy and radiotherapy resistance, also mortality. 2–4
Hypoxia also affects reactive oxygen species (ROS), where the
escalation of ROS increases HIF–1α stability in inflammatory
cells.5 ROS deals with the body's antioxidant system, namely
melatonin, which is an endogenous antioxidant. Systematic
reviews and meta–analysis of 21 clinical trials reported a
beneficial effect of melatonin with 10–40 mg/day in cancer
patients, in conjunction with or without standard
chemotherapy, given before or simultaneously with the
chemotherapy.6 Most clinical trials that employ oral melatonin
of 20 mg/day (0.3 mg/kg/day), given at night. A minimal dose
of melatonin required to exert its antitumor properties. 7
Melatonin also has oncostatic properties through inducing
apoptosis of cancer cells. Melatonin, given simultaneously with
chemotherapy in solid tumors, increases chemotherapy
response and survival. Nevertheless, there has not been an
experimental study that can explain melatonin's influence in
alleviating tumor clinical response to chemotherapy.

Literature searching carried out on four database sites
(PubMed, ClinicalKey, ScienceDirect, and Wiley Online
Library). The keywords used following medical subject

headings, namely: 'melatonin', 'oral squamous cell carcinoma',
'melatonin, and oral squamous cell carcinoma, and solid tumor'.
Fifty–eight studies included in this review.
Hypoxia in tumor
The hypoxic microenvironment caused by an imbalance in
oxygen supply and consumption. The limited blood supply in
the rapidly proliferating tumor impairs oxygen diffusion
leading to hypoxia. Several factors may lead to hypoxia,
namely pathological, physiological, emotional stress, and
unfavorable environment. Oxygen deficiency occurs in all
phases of growth and development of a solid tumor. Tumor
hypoxia is mainly due to the lack of organization of blood
vessels (new capillaries, angiogenesis) on the superficial layer
of a solid tumor. However, nearly none reside inside, resulting
in severe hypoxia in the center of the tumor mass. Hypoxic
stress in solid tumor causes uncontrolled HIF and VEGF
expression that triggers the proliferation and differentiation of
vascular endothelial cell, followed with the formation of new
blood vessels.1,4
In hypoxic state, cells may elicit response in three ways,
namely: (a) inhibition of cell proliferation to restrain the
number of cells that consume oxygen; (b) decrement of
oxidative phosphorylation and increment of glycolysis let
cellular oxygen consumption decreases, and (c) increased
production of angiogenic factors to enhance oxygen delivery. 8
Tissue hypoxia is a hallmark of nearly all solid tumors. It
regulates different processes of cellular metabolism, cell
survival and proliferation, angiogenesis, adhesion, and
motility.9 Adaptation to hypoxia is essential for tumor
expansion, invasion, metastasis. Such an adaptation well
recognized as treatment failure in clinical oncology. 10 Acute
hypoxic stress triggers the development of aggressive cancer
phenotype with rapid metastatic rate, resistance to therapeutic
agents, and higher tumor recurrence. Prolonged lack of oxygen
will generate chronic hypoxic stress and tumor necrosis. 1
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Hypoxia–Inducible Factor
HIF is known as a critical regulator in the cellular response to
hypoxia that holds an important role in the development of the
disease, especially cancer. The hypoxic tumors environment
leads to the stabilization of HIF. HIF is crucial in critical
biological aspects of cancer, namely in the angiogenesis
process, stem cell maintenance, metabolic reprogramming,
autocrine growth factor signaling, epithelial–mesenchymal
transition, invasion, metastasis, also resistance to radiation
therapy and chemotherapy.11 HIF comprise of HIF–1α, HIF–
1ß, HIF–2α, and HIF–3α. HIF–1α is the most important one of
which, responsible for the activation of hypoxia–related
transcriptional responses. HIF–1ß is a dimerization of HIF–1α,
while HIF–2α and HIF–3α are isoforms. HIF–2α functions are
similar to that of HIF–1α, which are to increase regulation of
transcriptional activity while HIF–3α roles as a down–regulator
in decreasing hypoxia response through HIF–1α mediator
inhibitor.3
The oxygen concentration activity governs the HIF–1α and
HIF–2α. In hypoxic conditions, these proteins degraded by the
proteasome. Unlike subunit β, HIF–1α regulated
intracellularly, which produced as a response to decreased
oxygen level.12 HIF is targeted for ubiquitination by oxygen–
sensitive prolyl hydroxylases (PHD) and von Hippel–Lindau
(VHL) tumor suppressor protein. In normoxic conditions,
Factor Inhibiting HIF–1 (FIH) also causes inactivation due to
HIF hydroxylation. In hypoxic conditions, there is a
stabilization of HIF–1α and HIF–2α due to hydroxylation and
HIF–1; all the mentioned factors undergo inhibition due to lack
of oxygen. In hypoxic conditions, HIF–1α bound to its dimer,
which is HIF–1β forming HIF–1, which later will translocate to
the nucleus. Furthermore, HIF–1 bound to specific regulatory
elements in target genes' promoters that induce its expression.13
Increased HIF–1α expression due to hypoxia and genetic
mutation occurs in various cancers in humans, such as
malignancy of the brain, breast, cervix, esophagus, oropharynx,
and ovarium. Increased expression of HIF–1α and HIF–2α in
the tumor is related to a more aggressive tumor phenotype and
unfavorable survival prognosis, which reflects the impact of
these factors on tumor development.9,14 Increased expression
also related to the resistance to chemotherapy, radiotherapy,
and mortality.4 HIF–1α plays an essential role in normal tumor
growth and development. However, there are conflicting
findings related to the theory. In the majority of cancer, HIF–
1α expression might be correlated with poor prognosis (p =
0.08)15 or can increase overall survival and disease–free
survival. Thus, it can be concluded that the effect of HIF–1α
expression depends explicitly on the type of cancer and the
presence of genetic changes that affect the balance of pro– and
antiapoptotic course.16

(R•), peroxyl radicals (ROO•), alkoxyl radicals (RO•), thiyl
radicals (RS•), sulfonyl radicals (ROS•), thiyl peroxyl radicals
(RSOO•), and disulfides (RSSR). Non–radicals comprised of
H2O2, singlet oxygen (1O2), ozone/trioxygen (O3), organic
hydroperoxides (ROOH), hypochloride (HOCl), peroxynitrite
(ONO‒), nitrosoperoxycarbonate anion (O=NOOCO2),
nitrocarbonate anion (O2NOCO2‒), dinitrogen dioxide (N2O2),
nitronium (NO2+), and carbonyl substance derived from highly
reactive lipid or carbohydrate. Superoxide, H 2O2, and radical
hydroxyl are the types of ROS that more commonly studied in
its relation to cancer.17
Several factors and ROS determine the number of free radicals.
Endogenous sources of ROS include mitochondria, metabolic
reaction through cytochrome P–450, peroxisome, and
activation of inflammatory cells. There are abundant cellular
systems that could produce ROS. Intracellular ROS primary
resource is the respiratory chain in mitochondria, which utilizes
80–90% oxygen consumed by an individual and produces the
majority of ROS in the body. Another source of ROS,
particularly in the liver, is a group of enzymes, also known as
cytochrome P–450 monooxygenase (mixed–function oxidase).
ROS is also produced by several enzymes intracellularly, such
as xanthine oxidase. In physiological condition, xanthine
oxidase act as a dehydrogenase, which releases hydrogen from
xanthine or hypoxanthine and attaches hydrogen to NAD,
therefore, forming NADH. In conditions such as disturbance of
tissue perfusion, xanthine dehydrogenase will be transformed
into ROS–producing oxidase.18–21
Mitochondria play a role in the control of ATP production
through electron chain transport, calcium homeostasis,
apoptosis, and cell signaling, while ROS is involved in
enhancing stabilization of HIF–1α in inflammatory cells.22–24
Accumulation of HIF is an impact of increased ROS by
NADPH oxidase.5 In hypoxic conditions, ROS is also produced
by mitochondria, which will activate ERK and p38 MAP kinase
pathway. Activated ERK2 will phosphorylate HIF–1α and
increase transcriptional activity (Figure 2.4). 25 Therefore, it is
crucial to recognize mechanisms underlying HIF regulation and
ROS production in cellular metabolism, oncogenesis, and stem
cell biology.5

Hypoxia–Inducible Factor and Reactive Oxygen Species
ROS is a substance or molecule which has a single unpaired
electron in its outer electron shell; therefore, ROS is highly
reactive. ROS categorized into two groups: free radicals and
nonradical. Free radicals are composed of superoxide (O2 •‒),
hydroxyl radical (•OH), nitric oxide (NO•), organic radicals

Figure 1. Primary Circuit of ROS signal regulation in normoxic and
hypoxic condition.25 Note. HIF–1α as a central node of the
communication network. Straight line depicts known relationships,
while the dashed line depicts relationships that require further
investigation.
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Effect of Hypoxia on Chemoresistance

Melatonin

Resistance to chemotherapy is the leading cause of therapy
failure in inoperable and advanced–stage cancer. Causes for
resistance are complex and can be divided into three group
factors which are; pharmacokinetic resistance, intrinsic tumor
cell resistance, and microenvironmental factors.26,27 Hypoxia
affects the microenvironment of stem cells and stemness
phenotype; regulation of cell population's resistance to
apoptosis; reduction of proapoptotic gene activity; autophagic
induction and anaerobic metabolism activation. Intratumor
hypoxia causes genomic instability through suppression of
DNA repair pathway and ROS production; it also contributes
to cellular resistance to radiotherapy and chemotherapy. 28

Melatonin is a naturally produced hormone secreted by the
pineal gland. In mammals, melatonin also synthesized by other
organs, such as eyes, bone marrow, gastrointestinal tract, skin,
and lymphocyte.36 Unlike other antioxidants, melatonin can
penetrate physiological barriers (including blood–brain barrier)
and still achieves therapeutic concentration. Melatonin
possesses two kinds of receptors that are bound to a G protein
in the target cell, namely MT1 and MT2.37 Radical–scavenging
effect of melatonin is not achieved through those receptors.
However, antioxidant enzyme activation involves these
receptors in target cells.38 Activation of these two receptors
influences the regulation of cellular processes, namely neuron
excitation, arterial vasoconstriction, cellular proliferation,
immune response, also other metabolic and reproductive
functions.37 Other than MT1 and MT2, melatonin also interacts
with the intracellular protein, namely ROR/RZR (located in the
nucleus), quinone reductase 2 (known as MT 3). Retinoid–
related orphan receptor (ROR)/retinoid Z receptor (RZR) is
related to MT1 and MT2 in regulating gene expression.39
Melatonin affects activity in almost every cell. It can be
detected in membrane compartment, cytoplasm, mitochondria,
and nucleus so that melatonin differs from any other hormones
in the sense that not synthesized by a single organ, possesses
nonspecific target organ, and has a dominant function of
protecting cells from free radicals.40,41 Melatonin also acts as a
potent antioxidant, immunomodulator, anti–proliferation,
oncostatic, and able to modulate endocrine glands.42 Melatonin
and its metabolite derivate is known as an antioxidant and
potent radical scavenger due to its ability to 'digest' 10 ROS by
forming antioxidant cascade so that it is far more effective than
other antioxidants.43

Hypoxia–induced chemoresistance first reported in the 1980s,
which elucidated that in chronic hypoxic conditions or severe
hypoxia, tumor cells may become chemo resistant. It was also
mentioned that hypoxia causes resistance of cancer cells to
therapy through the regulation of various processes, namely: 1)
Inducing cessation of cell cycle, through reduction of cell
proliferation which protects the cell from external stressor; 2)
Inhibiting apoptosis and cellular aging; 3) Controlling
autophagy, p53, and mitochondrial activity. 29,30 Irrespective of
several cellular adaptation mechanisms that are affected by
hypoxia, reduced oxygenation in tumor tissue causes
chemoresistance by affecting the drug delivery system and
cellular uptake through related acidity and expression of drug
efflux pump such as P–glycoprotein (P–gp) and decreasing
oxygen reserve that needed for chemotherapy cytotoxicity.31,32
Another critical point is that not only do cancer cells become
resistant to a single drug, but also several others (multidrug
resistance/MDR).
For growth, survival, and metastasis, cancer cells rely on their
distance to the blood vessel. Reliance on tumor cell
vascularization can be achieved through angiogenesis as
growth and tumor progression depends on this process. 33
Tumor cells located 100–200 μm from blood vessels will
become hypoxic, so to surpass the said limit, tumor cells will
undergo angiogenesis that is governed by the balance of pro–
angiogenic and anti–angiogenic molecules.34 In the initial
process of angiogenesis, small blood vessels rely on its major
blood vessel; no solid tumor can grow >2 mm 3 except by
synthesizing its new blood vessel.33
Hypoxia and expression of HIF–1 contributes in angiogenesis
through several ways, namely activating angiogenic genes and
its receptors through a transcription process (VEGF, Platelets–
derived growth factor (PlGF), PDGFB, Angiopoietin 1
(ANGPT1), and ANGPT2); regulating proangiogenic
chemokines and its receptors (SDF–1𝛼, stromal cell–derived
factor–1𝛼, S1P, sphingosine–1–phosphate, and CXCR4
receptor, C–X–C chemokine receptor type 4) thus facilitating
endothelial progenitor cells round–up in hypoxic area and
increasing proliferation and division of endothelial cell
(regulating gene in cell cycle and DNA replication).35

Melatonin's oncostatic effect is related to its ability to inhibit
tumor proliferation, induce apoptosis, prevent tumor cell
invasion and metastasis, angiogenesis, and improve cellular
immune activity.42,44 Clinical trial results of melatonin on non–
small cell lung cancer patients showed it could improve
effectivity and reduce side effects of chemotherapy, improve
survival rate, and improve patients' quality of life. 45
With 2 mg and 4 mg orally, only 15% reaches up systemic
circulation (bioavailability 15%), while the remaining 85%
most likely undergo the first–pass metabolism.46 This low
bioavailability may be caused by low absorption from the
digestive tract, liver first–pass metabolism, or both.47 The
central metabolism in the liver converts melatonin into its
metabolite through hydroxylation and conjugation by sulfate or
glucuronic acid; then, it excreted through urine. 48
Melatonin is mainly metabolized in the liver by enzyme
cytochrome P450 enzymes, which are CYP1A2, CYP1A1, and
CYP1B1.42 Melatonin is degraded by CYP1A2, thus competing
with coffee and tea. T1/2 of caffeine during melatonin release is
prolonged, and caffeine consumption delays attainment of peak
melatonin concentration at nighttime.49 Melatonin has a
hydrophilic and lipophilic characteristic, its lipophilic property
enables it to penetrate every biological membrane, including
the blood–brain barrier.50 In circulation, 70% of melatonin
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binds to albumin while the rest (30%) diffuses freely into the
tissue.51 There had been numerous studies that explain the
effect of melatonin in vitro or in vivo. Melatonin can reduce
tumor cell growth and possesses anti carcinogenesis property. 52
Optimal dose for melatonin that commonly used in clinical
trials is 20–40 mg.6 Another effect of melatonin administration,
in combination with adjuvant chemotherapy, is a significant
reduction of adverse chemotherapy effects (nausea, vomiting,
anemia, asthenia, leukopenia, and thrombocytopenia). 6

6.

Melatonin inhibits HIF–1α, a gene induced by HIF–1α and
VEGF. In an in vitro study, melatonin inhibits expression of
HIF–1α of prostate cancer cells, glioblastoma, VEGF
expression in breast cancer cells, pancreatic cancer, liver
cancer, and glioblastoma.53–56 In Ewing sarcoma cell, tumor
cell displays metabolic profile consistent with aerobic
glycolysis such as an increase in glucose uptake, LDH activity,
lactate production, and HIF–1α activation. Melatonin restores
the metabolic profile of Ewing sarcoma–associated with
cytotoxicity.57

9.

Research on solid tumors conducted by Lissoni et al. .58
concludes that the administration of melatonin in combination
with chemotherapy can decrease the 1st year risk of death
significantly (p <0.001) and increase response rate (p <0.001)
compared to chemotherapy alone. The use of 20 mg melatonin
per day on cancer patients in the long term does not show any
significant toxicity effect.58

13.

Melatonin administration thought to affect tumor
microenvironment through lowering HIF–1 expression,
resulting in decreased angiogenesis, increased apoptosis.
Alleviation of hypoxia hoped to ameliorate tumor cells'
response towards chemotherapy and radiotherapy.

7.

8.

10.
11.

12.

14.
15.

16.

17.

Conclusion
Hypoxia in the microenvironment of solid tumors gives rise to
a series of events, namely increased expression of HIF–1α,
angiogenesis, and many more, which will cause
chemoresistance and radio–resistance, resulting in treatment
failure. Melatonin administration may improve hypoxia, thus
ameliorate treatment response.

18.
19.
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21.
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